

CLAIMS

1. An antisense oligonucleotide characterized in that it hybridizes specifically with chromosomal DNA and/or mRNA
5 encoding human interleukin-10(IL-10) protein to thereby inhibit the IL-10 protein expression, and it has any one or more of the following Sequences (A) to (G):

(A) Sequence described in SEQ ID NO:1 in the SEQUENCE LISTING

(B) Sequence described in SEQ ID NO:2 in the SEQUENCE LISTING

10 (C) Sequence described in SEQ ID NO:3 in the SEQUENCE LISTING

(D) Sequence described in SEQ ID NO:4 in the SEQUENCE LISTING

(E) Sequence described in SEQ ID NO:5 in the SEQUENCE LISTING

(F) Sequence described in SEQ ID NO:6 in the SEQUENCE LISTING

(G) Sequence described in SEQ ID NO:7 in the SEQUENCE LISTING.

15

2. A pharmaceutical agent containing the antisense oligonucleotide as described in Claim 1 as an effective component for the treatment of atopic dermatitis, allergodermia, systemic lupus erythematosus, Epstein-Barr
20 virus infectious disease or lymphoma.